Lista de obras -

A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis

artículo científico publicado en 2016

A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma

artículo científico publicado en 2012

A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.

artículo científico publicado en 2017

A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit

article

A genome-wide association study for malignant mesothelioma risk.

artículo científico publicado en 2013

A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.

artículo científico publicado en 2006

A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma

artículo científico publicado en 2013

A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma

artículo científico publicado en 2019

Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma

artículo científico publicado en 2015

Advances in pathological diagnosis of mesothelioma: what pulmonologists should know

artículo científico publicado en 2019

Association of biomarker levels with severity of asbestos-related diseases

artículo científico publicado en 2012

Author's response: Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies

artículo científico publicado en 2014

Auto-antibodies to β-F1-ATPase and vimentin in malignant mesothelioma

artículo científico publicado en 2011

Autoimmune antibodies and asbestos exposure: Evidence from Wittenoom, Western Australia

article

Bacterial infection elicits heat shock protein 72 release from pleural mesothelial cells

artículo científico publicado en 2013

Blood-based early detection of malignant mesothelioma

artículo científico publicado en 2008

Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life

artículo científico publicado en 2019

Calretinin as a blood-based biomarker for mesothelioma

artículo científico publicado en 2017

Clump material within drainage chest tubes contain diagnostic information: A proof-of-concept case series

artículo científico publicado en 2020

Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma

scientific article published on 23 July 2007

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma

artículo científico publicado en 2014

Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma

artículo científico

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma

artículo científico publicado en 2008

Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum

artículo científico publicado en 2013

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

artículo científico

Comprehensive Characterization of Cancer Driver Genes and Mutations

article

Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma

scientific article published on 30 May 2022

Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma

artículo científico publicado en 2015

Correction: genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.

artículo científico publicado en 2015

Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein

artículo científico publicado en 2005

Diagnoses (Not Diagnosis) of Pleural Effusion. Time to Consider Concurrent Etiologies.

artículo científico publicado en 2016

Discovery of new biomarkers for malignant mesothelioma

artículo científico publicado en 2015

Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?

artículo científico publicado en 2013

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms

artículo científico publicado en 2016

Endomicroscopy of the pleura highlights challenges and limitations of pleuroscopy

artículo científico publicado en 2020

Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms

artículo científico publicado en 2016

Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway

scientific article published on 19 October 2016

Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population

artículo científico publicado en 2010

Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.

artículo científico publicado en 2013

Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing.

artículo científico publicado en 2018

Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the [...]

artículo científico publicado en 2015

Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou

artículo científico publicado en 2015

Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou

artículo científico publicado en 2015

Histologically Diverse BAP1-Deficient Melanocytic Tumors in a Patient With BAP1 Tumor Predisposition Syndrome

artículo científico publicado en 2020

Hyaluronic acid in viscous malignant mesothelioma pleural effusion

scientific article published on 03 December 2020

Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma

artículo científico publicado en 2019

Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers

artículo científico

Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies

artículo científico publicado en 2016

Immunotherapy strategies for mesothelioma - the role of tumor specific neoantigens in a new era of precision medicine

artículo científico publicado en 2018

Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma.

artículo científico publicado en 2012

Integrative Molecular Characterization of Malignant Pleural Mesothelioma

artículo científico publicado en 2018

Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions.

artículo científico publicado en 2016

Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.

artículo científico publicado en 2018

Malignant mesothelioma biomarkers - from discovery to use in clinical practise for diagnosis, monitoring, screening and treatment

artículo científico publicado en 2016

Malignant pleural fluid from mesothelioma has potent biological activities.

artículo científico publicado en 2016

Mesothelial cells activate the plasma kallikrein-kinin system during pleural inflammation.

artículo científico publicado en 2011

Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening

artículo científico publicado en 2011

Mesothelin-family proteins and diagnosis of mesothelioma

artículo científico publicado en 2003

Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study

artículo científico publicado en 2008

MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions

scientific article published on 31 July 2019

Mitochondria-derived reactive oxygen species drive GANT61-induced mesothelioma cell apoptosis.

artículo científico publicado en 2015

Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?

artículo científico publicado en 2011

Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma

artículo científico publicado en 2013

Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.

artículo científico publicado en 2014

Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome

artículo científico publicado en 2019

Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters

artículo científico publicado en 2016

Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol

scientific article published on 01 March 2020

Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma

scientific article published on 24 March 2006

Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.

artículo científico publicado en 2016

Sensitivity of urinary mesothelin in patients with malignant mesothelioma

artículo científico publicado en 2010

Serum and pleural fluid biomarkers for mesothelioma

artículo científico publicado en 2009

Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis

artículo científico publicado en 2012

Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma

artículo científico

Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.

artículo científico publicado en 2010

Simplified Criteria Using Pleural Fluid Cholesterol and Lactate Dehydrogenase to Distinguish between Exudative and Transudative Pleural Effusions

artículo científico publicado en 2019

Soluble Mesothelin Related Protein in Mesothelioma

article

Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma

artículo científico publicado en 2007

Soluble mesothelin related protein in mesothelioma

scientific article published on 01 February 2006

Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study

artículo científico publicado en 2008

Soluble mesothelin-related protein--a blood test for mesothelioma

artículo científico publicado en 2005

Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen

artículo científico publicado en 2015

The BLM helicase is necessary for normal DNA double-strand break repair.

artículo científico publicado en 2002

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

article

The continual search for ideal biomarkers for mesothelioma: the hurdles.

artículo científico publicado en 2013

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma

artículo científico publicado en 2011

Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma ⬇️

artículo científico publicado el 1 de abril de 2013

Transient Treg depletion enhances therapeutic anti-cancer vaccination.

artículo científico publicado en 2016

Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors

article

Verification of a blood based targeted proteomics signature for malignant pleural mesothelioma

artículo científico publicado en 2020

Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma

artículo científico publicado en 2017

Lista de obras de

A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis

A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma

A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.

A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit

A genome-wide association study for malignant mesothelioma risk.

A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.

A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma

A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma

Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma

Advances in pathological diagnosis of mesothelioma: what pulmonologists should know

Association of biomarker levels with severity of asbestos-related diseases

Author's response: Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies

Auto-antibodies to β-F1-ATPase and vimentin in malignant mesothelioma

Autoimmune antibodies and asbestos exposure: Evidence from Wittenoom, Western Australia

Bacterial infection elicits heat shock protein 72 release from pleural mesothelial cells

Blood-based early detection of malignant mesothelioma

Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life

Calretinin as a blood-based biomarker for mesothelioma

Clump material within drainage chest tubes contain diagnostic information: A proof-of-concept case series

Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma

Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma

Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

Comprehensive Characterization of Cancer Driver Genes and Mutations

Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma

Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma

Correction: genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.

Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein

Diagnoses (Not Diagnosis) of Pleural Effusion. Time to Consider Concurrent Etiologies.

Discovery of new biomarkers for malignant mesothelioma

Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms

Endomicroscopy of the pleura highlights challenges and limitations of pleuroscopy

Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms

Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway

Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population

Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.

Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing.

Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the [...]

Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou

Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou

Histologically Diverse BAP1-Deficient Melanocytic Tumors in a Patient With BAP1 Tumor Predisposition Syndrome

Hyaluronic acid in viscous malignant mesothelioma pleural effusion

Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma

Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers

Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies

Immunotherapy strategies for mesothelioma - the role of tumor specific neoantigens in a new era of precision medicine

Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma.

Integrative Molecular Characterization of Malignant Pleural Mesothelioma

Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions.

Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.

Malignant mesothelioma biomarkers - from discovery to use in clinical practise for diagnosis, monitoring, screening and treatment

Malignant pleural fluid from mesothelioma has potent biological activities.

Mesothelial cells activate the plasma kallikrein-kinin system during pleural inflammation.

Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening

Mesothelin-family proteins and diagnosis of mesothelioma

Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study

MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions

Mitochondria-derived reactive oxygen species drive GANT61-induced mesothelioma cell apoptosis.

Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?

Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma

Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.

Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome

Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters

Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol

Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma

Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.

Sensitivity of urinary mesothelin in patients with malignant mesothelioma

Serum and pleural fluid biomarkers for mesothelioma

Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis

Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma

Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.

Simplified Criteria Using Pleural Fluid Cholesterol and Lactate Dehydrogenase to Distinguish between Exudative and Transudative Pleural Effusions

Soluble Mesothelin Related Protein in Mesothelioma

Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma

Soluble mesothelin related protein in mesothelioma

Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study